Drug Approval | March 25, 2022
USFDA approves Janssen’s injectable regimen for HIV
Cabenuva was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's decades-long commitment to combatting HIV
Cabenuva was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's decades-long commitment to combatting HIV
Titan 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
The test can overcome the time and cost limitations of traditional culture-based drug susceptibility testing as it can more rapidly detect all mutations known to be associated with drug resistance for any TB drug in one step
Organizations to combine expertise to further develop AI/ML-powered drug design platform, delivering precise, effective, and life-changing medicines at scale
This drive will expand access to quality diagnostics and help find the ‘missing millions’ – patients that are suffering from TB but not registered in the healthcare system
A staggering 65% of the TB cases in India are in the 15-45 age group
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
The product will be manufactured at Lupin’s facility in Goa, India
USFDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions
Subscribe To Our Newsletter & Stay Updated
